Single-Organ Focus
Mammograms, colonoscopies and Pap smears only detect one cancer at a time— leaving many other cancers unmonitored.
Multi-Cancer Early Detection
- Home
- Services
- Multi-Cancer Early Detection
Multi-Cancer Early Detection (MCED) · DNA cancer test · ctDNA methylation test · early cancer screening · liquid biopsy cancer test · non-invasive cancer screening in Kuala Lumpur
Limited-time
RM 2,199.00
Comprehensive, non-invasive cancer screening in KL for up to 16 cancer types in a single blood test.
Multi-Cancer Early Detection (MCED) is an advanced cancer screening method that uses a simple blood test to detect early signs of multiple cancers at once. It functions as a highly sensitive DNA cancer test that looks for cancer signals at the molecular level.
Unlike traditional screening that focuses on one organ at a time, MCED analyses circulating tumour DNA (ctDNA) in your bloodstream to identify cancer signals before symptoms develop. It is a modern form of liquid biopsy, giving you a whole-body view of cancer risk in a single, non-invasive cancer screening.
Most cancers are silent in their early stages. By the time symptoms such as unexplained weight loss, chronic fatigue or persistent pain appear, the disease is often already advanced.
When cancer is detected early (Stage I), 5-year survival rates for many common cancers can exceed 90%. In contrast, late-stage detection (Stage III–IV) is associated with significantly lower survival and far more complex, intensive treatment.
Early detection does not just improve survival. It can reduce treatment complexity, cost and physical burden—helping preserve your quality of life.
5-year survival for many cancers when detected early
Survival drops significantly, with more aggressive treatment needed
Single-Organ Focus
Mammograms, colonoscopies and Pap smears only detect one cancer at a time— leaving many other cancers unmonitored.
Late Detection Biomarkers
Many traditional blood tests detect proteins that typically appear only in later stages of cancer, limiting their usefulness for ultra-early detection.
Invasive Procedures
Many screenings are uncomfortable and invasive, often requiring bowel preparation, sedation or surgery—discouraging people from regular checks.
False Positives from Imaging
Imaging scans may detect harmless abnormalities, leading to unnecessary follow-ups, anxiety and repeat procedures.
Traditional methods often detect cancer too late—Multi-Cancer Early Detection (MCED) changes that.
This Multi-Cancer Early Detection test uses ctDNA methylation analysis, the most advanced form of liquid biopsy. It looks at epigenetic "on/off" switches on DNA, rather than waiting for large tumours to appear on scans.
Key benefit: this ctDNA methylation test can detect cancer at Stage 0–I, before tumours are visible on scans.
Detects cancer earlier
Identifies ultra-early methylation changes, often before tumours can be seen on imaging or cause symptoms.
Highly specific, low false positives
Focuses on cancer-specific epigenetic signatures, reducing the risk of false alarms compared to many older tests.
Works across multiple cancers
A single ctDNA methylation test can screen for signals linked to up to 16 different cancer types.
Not affected by normal ageing mutations
Unlike some mutation-based tests, methylation analysis is less affected by benign age-related DNA changes.
This is currently one of the most advanced early cancer screening technologies available for patients seeking high-accuracy, non-invasive cancer screening.
Comprehensive multi-cancer screening in one test—without multiple invasive procedures.
This MCED DNA cancer test is suitable for adults who want a proactive, non-invasive way to assess their cancer risk—especially if one or more of the following applies to you:
Cancer risk increases with age. From 40 years onwards, early molecular screening becomes an important addition to routine health checks.
If your parents, siblings or close relatives have had cancer, you may have a higher inherited or epigenetic risk and benefit from earlier screening.
Smokers or former smokers, high-stress or sedentary lifestyles, unhealthy diets, and exposure to toxins or pollution can increase cancer risk.
If you want peace of mind and prefer to detect problems before symptoms appear, this non-invasive cancer screening is designed for you.
Simple positioning: if you want peace of mind and proactive control over your health, this test is for you.
You can access this advanced Multi-Cancer Early Detection test in Kuala Lumpur at trusted clinics equipped with certified laboratories and experienced medical teams.
All samples are processed in accredited genomic laboratories using state-of-the-art sequencing and ctDNA methylation analysis. Doctor consultation is available to help you understand your results and decide on the next step.
Review a real EpiSure16 sample report and patient information pamphlet to understand how your Multi-Cancer Early Detection results will be presented and how the test works.
These documents are for educational purposes and illustration only. Your actual report and advice will be personalised by your doctor.
Standard Price: RM 2,199.00
Claim your voucher and book your Multi-Cancer Early Detection (MCED) screening in Kuala Lumpur today.
🎁 GET RM 200 DISCOUNT VOUCHER NOW!Mention this Multi-Cancer Early Detection webpage to redeem your RM 200 voucher.
This Multi-Cancer Early Detection test is a powerful screening tool, but it does not replace clinical evaluation and follow-up with your doctor.
A high or moderate risk result means that abnormal ctDNA methylation signals associated with cancer were detected. It does not diagnose cancer. Further diagnostic tests (such as imaging or biopsy) are required to confirm if cancer is truly present.
A low-risk result means no cancer-associated ctDNA methylation was detected at the time of testing. It does not guarantee that cancer will never develop. Regular health check-ups and age-appropriate screening are still recommended.
How different blood-based cancer detection methods compare in accuracy, timing, and clinical use.
| Feature | CTC (Circulating Tumor Cells) | Standard ctDNA (Mutations) | ctDNA-based Methylation Method |
|---|---|---|---|
| Primary Target Analyzed | Whole, intact tumor cells | Genetic mutations / Sequence typos | Epigenetic "On/Off" switches |
| Detection Stage Capability | Late Stage (Metastatic/Spreading) | Moderate to Early Stage | Ultra-Early (Stage I / Asymptomatic) |
| False Positive Rate | Low | High (confused by natural aging/CHIP) | Extremely Low (Highly Specific & Accurate) |
| Scope of Detection | Limited strictly to shedding tumors | Specific to known, mapped mutations | Broad (Detects multiple cancer types universally) |
| Best Clinical Use Case | Monitoring existing advanced cancer | Targeted therapy selection for patients | Proactive Multi-Cancer Early Detection |
Don't wait for symptoms to appear. Detect cancer early with one of the most advanced DNA cancer screening tests available in Kuala Lumpur.
Multi-Cancer Early Detection (MCED) · ctDNA methylation test · non-invasive liquid biopsy cancer test for the Klang Valley and greater KL area.
